Home LiteratureArticle Details
PMID: 24178189 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Development of universal influenza vaccines based on influenza virus M and NP genes.

Infection ·Vol. 42 ·No. 2 ·2014-04-00 ·Pages 251-62

Zheng M, Luo J, Chen Z

Abstract

Vaccination is the safest and most effective measure against influenza virus infections. However, traditional influenza vaccines cannot respond effectively to an unforeseen epidemic or pandemic caused by a virus with antigenic drifts or antigenic shifts. Therefore, developing a universal influenza vaccine (UIV) that induces broad-spectrum and long-term immunity has become a major trend in influenza vaccine research and development. This article reviews the development of UIVs based on these conserved influenza virus proteins. The matrix protein (M1, M2) and nucleoprotein (NP) of influenza viruses have highly conserved sequences, and they become the major target antigens of current UIV studies.

MeSH Terms
Animals Chickens Humans Influenza Vaccines/genetics,immunology Influenza in Birds/immunology,prevention & control,virology Influenza, Human/immunology,prevention & control,virology Mice Nucleocapsid Proteins Orthomyxoviridae/genetics,immunology Orthomyxoviridae Infections/immunology,prevention & control,virology RNA-Binding Proteins/genetics,immunology,metabolism Viral Core Proteins/genetics,immunology,metabolism Viral Matrix Proteins/genetics,immunology,metabolism
Chemicals
Influenza Vaccines M1 protein, Influenza A virus M2 protein, Influenza A virus NP protein, Influenza A virus Nucleocapsid Proteins RNA-Binding Proteins Viral Core Proteins Viral Matrix Proteins
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Zheng M
Shanghai Institute of Biological Products, Shanghai, 200052, China.
Luo J
Chen Z
References (69)
69 references, click to expand
  1. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Vaccine. 2010 Nov 10;28(48):7690-8 PMID: 20870054
  2. Detection and quantification of CD4(+) T cells with specificity for a new major histocompatibility complex class II-restricted influenza A virus matrix protein epitope in peripheral blood of influenza patients.
    J Virol. 2000 Sep;74(18):8740-3 PMID: 10954576
  3. Stimulation of mucosal and systemic antibody responses against recombinant transferrin-binding protein B of Actinobacillus pleuropneumoniae with chitosan after tracheal administration in piglets.
    J Vet Med Sci. 2007 May;69(5):535-9 PMID: 17551229
  4. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.
    Vaccine. 2008 Apr 16;26(17):2062-72 PMID: 18378366
  5. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Vaccine. 2008 Feb 26;26(9):1243-52 PMID: 18243429
  6. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes.
    Proc Natl Acad Sci U S A. 1985 Mar;82(6):1785-9 PMID: 3872457
  7. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene.
    Vaccine. 2001 Jun 14;19(27):3681-91 PMID: 11395202
  8. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus.
    J Gen Virol. 2002 Aug;83(Pt 8):1851-1859 PMID: 12124449
  9. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.
    Clin Infect Dis. 2012 Jul;55(1):19-25 PMID: 22441650
  10. Intraepithelial cell neutralization of HIV-1 replication by IgA.
    J Immunol. 2005 Apr 15;174(8):4828-35 PMID: 15814709
  11. Cell-mediated protection in influenza infection.
    Emerg Infect Dis. 2006 Jan;12(1):48-54 PMID: 16494717
  12. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.
    PLoS One. 2008 May 21;3(5):e2257 PMID: 18493310
  13. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin.
    PLoS One. 2010 Dec 28;5(12):e14442 PMID: 21203437
  14. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Vaccine. 2008 Jan 10;26(2):201-14 PMID: 18063235
  15. Immunoglobulin A antibodies against internal HIV-1 proteins neutralize HIV-1 replication inside epithelial cells.
    Virology. 2006 Dec 5-20;356(1-2):165-70 PMID: 16956641
  16. Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.
    Vaccine. 2013 Jan 11;31(4):670-5 PMID: 23200938
  17. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies.
    J Virol. 1995 Feb;69(2):1339-43 PMID: 7815518
  18. Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.
    J Clin Immunol. 2012 Jun;32(3):595-603 PMID: 22318394
  19. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults.
    Vaccine. 2010 Dec 6;28(52):8268-74 PMID: 20969925
  20. Modified M2 proteins produce heterotypic immunity against influenza A virus.
    Vaccine. 1999 May 4;17(18):2237-44 PMID: 10403591
  21. Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus.
    Viral Immunol. 2011 Feb;24(1):45-56 PMID: 21319978
  22. Intracellular neutralization of virus by immunoglobulin A antibodies.
    Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6901-5 PMID: 1323121
  23. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein.
    J Gen Virol. 1999 Oct;80 ( Pt 10):2559-2564 PMID: 10573147
  24. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.
    Virol J. 2010 Jul 12;7:151 PMID: 20624292
  25. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus.
    Vaccine. 2002 Jun 21;20(21-22):2772-80 PMID: 12034104
  26. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.
    Eur J Immunol. 2008 Jan;38(1):114-26 PMID: 18081037
  27. Purified influenza virus nucleoprotein protects mice from lethal infection.
    J Gen Virol. 1987 Feb;68 ( Pt 2):433-40 PMID: 3493324
  28. Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route.
    Vet Res Commun. 2009 Oct;33(7):735-47 PMID: 19462253
  29. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.
    Vaccine. 2009 Oct 9;27(43):6022-9 PMID: 19666152
  30. The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice.
    Virology. 2003 May 10;309(2):320-9 PMID: 12758178
  31. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions.
    J Virol. 1988 Aug;62(8):2762-72 PMID: 2455818
  32. CD4+ and CD8+ mediated cellular immune response to recombinant influenza nucleoprotein.
    Vaccine. 2002 Nov 1;20(31-32):3731-8 PMID: 12399202
  33. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein.
    J Immunol. 1996 May 15;156(10):3892-900 PMID: 8621928
  34. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice.
    J Virol. 1990 Mar;64(3):1375-7 PMID: 2304147
  35. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination.
    Vaccine. 1997 Jun;15(8):865-8 PMID: 9234535
  36. Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus.
    Virus Genes. 2009 Feb;38(1):30-8 PMID: 19067149
  37. Multimeric-001: BiondVax's universal flu vaccine. Interview by Duc Le.
    Expert Rev Vaccines. 2010 Mar;9(3):241-2 PMID: 20218850
  38. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein.
    Vaccine. 1995;13(15):1399-402 PMID: 8578816
  39. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins.
    J Virol. 1991 Oct;65(10):5491-8 PMID: 1895397
  40. Induction of T cell response by bluetongue virus core-like particles expressing a T cell epitope of the M1 protein of influenza A virus.
    Med Microbiol Immunol. 1998 Oct;187(2):91-6 PMID: 9832322
  41. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge.
    Mol Ther. 2010 Dec;18(12):2182-9 PMID: 20877342
  42. Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins.
    Proc Natl Acad Sci U S A. 1981 Jul;78(7):4170-4 PMID: 6945577
  43. Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype.
    Vaccine. 2010 Sep 24;28(41):6704-13 PMID: 20691653
  44. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein.
    Arch Virol. 2010 Nov;155(11):1765-75 PMID: 20652335
  45. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.
    Vaccine. 2008 Jun 25;26(27-28):3395-403 PMID: 18511159
  46. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
    Vaccine. 2006 Jan 30;24(5):544-51 PMID: 16169634
  47. Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli.
    PLoS One. 2012;7(12):e52488 PMID: 23285063
  48. Novel generations of influenza vaccines.
    Vaccine. 2003 May 1;21(16):1789-95 PMID: 12686096
  49. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
    PLoS One. 2012;7(10):e48322 PMID: 23118984
  50. Efficacy of parainfluenza virus 5 mutants expressing hemagglutinin from H5N1 influenza A virus in mice.
    J Virol. 2013 Sep;87(17):9604-9 PMID: 23804633
  51. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.
    Vaccine. 2004 Aug 13;22(23-24):2993-3003 PMID: 15297047
  52. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.
    Vaccine. 2003 Jun 2;21(19-20):2616-26 PMID: 12744898
  53. A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus.
    PLoS One. 2011;6(10):e25938 PMID: 21998725
  54. M2e-based universal influenza A vaccine.
    Vaccine. 2009 Oct 23;27(45):6280-3 PMID: 19840661
  55. Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model.
    J Virol. 2002 Nov;76(21):10972-9 PMID: 12368340
  56. Transcription-inhibition and RNA-binding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides.
    J Virol. 1989 Sep;63(9):3586-94 PMID: 2474671
  57. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines.
    Vaccine. 2006 Jun 12;24(24):5158-68 PMID: 16713037
  58. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.
    Vaccine. 2011 Jul 18;29(32):5145-52 PMID: 21624416
  59. Unpacking the incoming influenza virus.
    Cell. 1992 May 15;69(4):577-8 PMID: 1375129
  60. Pandemic preparedness: toward a universal influenza vaccine.
    Drug News Perspect. 2009 Mar;22(2):80-92 PMID: 19330167
  61. A universal influenza A vaccine based on the extracellular domain of the M2 protein.
    Nat Med. 1999 Oct;5(10):1157-63 PMID: 10502819
  62. Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier.
    J Pharm Sci. 2006 Jan;95(1):70-9 PMID: 16315228
  63. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Arch Virol. 2010 Apr;155(4):535-44 PMID: 20195654
  64. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.
    Mol Ther. 2014 Jan;22(1):233-8 PMID: 23831594
  65. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.
    J Biol Chem. 2008 Apr 25;283(17):11382-7 PMID: 18252707
  66. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine.
    PLoS One. 2012;7(3):e33428 PMID: 22432020
  67. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.
    Emerg Infect Dis. 2007 Mar;13(3):426-35 PMID: 17552096
  68. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.
    Expert Rev Vaccines. 2009 Apr;8(4):499-508 PMID: 19348565
  69. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
    Vaccine. 2010 Oct 18;28(44):7233-40 PMID: 20732469
Article Info
Journal
Infection
Abbr.
Infection
ISSN
1439-0973
DOI
10.1007/s15010-013-0546-4
Published
2014-04-00
Epub
2013-00-01
Pages
251-62
Language
English
Region
Germany
NLM ID
0365307
Subset
IM
External Links
PubMed source DOI: 10.1007/s15010-013-0546-4 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2